Shandong Boan Biotechnology Company., Limited. Class H

As of December 31, 2025, Shandong Boan Biotechnology Company., Limited. Class H carries a market capitalization of 5.31B, placing it among publicly traded companies globally. Its enterprise value stands at 4.93B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Shandong Boan Biotechnology Company., Limited. Class H's next confirmed earnings release is scheduled for March 29, 2027.

As of December 31, 2025, Shandong Boan Biotechnology Company., Limited. Class H has 622.33M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Shandong Boan Biotechnology Company., Limited. Class H maintains a current ratio of 2.33, meaning it holds 2.3x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, Shandong Boan Biotechnology Company., Limited. Class H's stock has declined approximately 73.11% over the past 52 weeks. The 50-day moving average sits at 3.32, while the 200-day moving average is 5.76.

As of December 31, 2025, Shandong Boan Biotechnology Company., Limited. Class H holds 1.26B in cash and equivalents against 871.70M in total debt, resulting in a net debt position of -386.31M. Total book value stands at 3.05B, with working capital of 1.28B providing operational flexibility.